StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a research report sent to investors on Friday. The firm issued a hold rating on the biotechnology company's stock.

A number of other equities research analysts also recently weighed in on CALA. SVB Leerink downgraded Calithera Biosciences from an outperform rating to a market perform rating in a research report on Tuesday, November 15th. LADENBURG THALM/SH SH downgraded Calithera Biosciences from a buy rating to a neutral rating in a report on Tuesday, November 15th.

Calithera Biosciences Stock Up 17.6 %

CALA stock opened at $0.06 on Friday. The company has a market cap of $292,200.00, a P/E ratio of 0.00 and a beta of 1.22. Calithera Biosciences has a twelve month low of $0.05 and a twelve month high of $13.38. The business has a fifty day moving average of $0.84 and a 200-day moving average of $2.09.

Insider Activity at Calithera Biosciences

In related news, Director Deepika Pakianathan sold 121,333 shares of the company's stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $0.39, for a total value of $47,319.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Calithera Biosciences

Several large investors have recently modified their holdings of the business. TSP Capital Management Group LLC increased its holdings in shares of Calithera Biosciences by 18.0% in the third quarter. TSP Capital Management Group LLC now owns 62,900 shares of the biotechnology company's stock worth $185,000 after acquiring an additional 9,605 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Calithera Biosciences by 13.8% during the third quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company's stock worth $337,000 after buying an additional 13,855 shares during the period. Vanguard Group Inc. boosted its position in shares of Calithera Biosciences by 23.4% during the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock worth $415,000 after buying an additional 26,800 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Calithera Biosciences by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock worth $50,000 after buying an additional 72,865 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Calithera Biosciences during the first quarter worth about $404,000. 33.73% of the stock is currently owned by institutional investors.

About Calithera Biosciences

(Get Rating)

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.

Recommended Stories

• Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
• Go Where the Money Is. Here's 3 Top Bank Dividend Stocks to Buy
• Another Catalyst For Mullen Automotive Stock
• Solar Tech-Services; Nextracker Should Be On Your Radar
• Is American Lithium a Safe Bet as Demand for Lithium Soars
• Highwoods Properties, High-quality Real Estate for a Discount

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.